Trans-arterial Chemoembolization (TACE) is an interventional radiology procedure that delivers anti-cancer medication (chemotherapy) and embolizing materials directly into blood vessels feeding a malignant liver tumor. TACE is a two-pronged approach that can simultaneously limit the blood supply feeding a tumor in order to destroy cancerous cells (embolization) while the chemotherapy prevents further growth.Transarterial Chemoembolization (TACE) is a minimally invasive procedure in which chemotherapy and embolic agents are directly delivered to a cancerous tumour via its blood supply. The embolic agents are used to cut off the blood supply to the tumour without affecting the rest of the liver. Compared to receiving conventional chemotherapy, TACE allows for the maximum amount of chemotherapy agent to reach the tumour, while limiting the amount released into the bloodstream.
The global market for Transarterial Chemoembolization (TACE) was estimated to be worth US$ 10930 million in 2023 and is forecast to a readjusted size of US$ 18970 million by 2030 with a CAGR of 8.3% during the forecast period 2024-2030
The global Transarterial Chemoembolization (TACE) market refers to the market for a minimally invasive procedure used in the treatment of liver cancer. TACE is a locoregional therapy that combines chemotherapy and embolization to deliver anticancer drugs directly to the tumor site while blocking the blood supply to the tumor.
Liver cancer, specifically hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths worldwide. TACE has emerged as a commonly used treatment option for patients with intermediate-stage HCC or those who are not eligible for surgical resection or liver transplantation.
The TACE procedure involves the insertion of a catheter into the hepatic artery, the main blood supply to the liver. Through the catheter, a drug-eluting bead or emulsion containing chemotherapeutic agents is infused directly into the tumor, followed by the injection of embolic agents to occlude the blood vessels feeding the tumor. This dual action targets the tumor cells and restricts their blood supply, thereby delaying tumor growth and potentially shrinking the tumor.
Some key factors driving the global TACE market include:
Increasing incidence of liver cancer: The rising prevalence of liver cancer, particularly HCC, has led to an increased demand for effective treatment options. TACE offers a targeted approach for patients with intermediate-stage HCC, who represent a significant portion of liver cancer cases.
Limited surgical options: Liver resection and transplantation remain the most effective treatment options for early-stage HCC. However, many patients are not eligible for surgery due to the size and location of the tumor, underlying liver disease, or other patient factors. TACE provides a non-surgical alternative for these patients.
Advancements in imaging and catheterization techniques: The advancements in imaging technologies, such as computed tomography (CT) and fluoroscopy, have improved the precision and safety of TACE procedures. Additionally, the development of better catheterization techniques and embolic agents has enhanced the effectiveness and outcomes of TACE.
Multidisciplinary approach to cancer treatment: TACE is often used as part of a multidisciplinary approach to treating liver cancer. It may be combined with other interventions, such as radiofrequency ablation, sorafenib therapy, or immunotherapy, to achieve better treatment outcomes.
The global TACE market includes various players, including medical device manufacturers, pharmaceutical companies, and healthcare providers offering TACE equipment, drugs, and related services. Additionally, research and development activities are continually focused on improving the effectiveness and safety of TACE procedures and developing innovative embolic agents and drug formulations.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Transarterial Chemoembolization (TACE), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Transarterial Chemoembolization (TACE) by region & country, by Type, and by Application.
The Transarterial Chemoembolization (TACE) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transarterial Chemoembolization (TACE).
Market Segmentation
By Company
Questex
Siemens Healthcare GmbH
Bellicum Pharmaceuticals Inc.
Boston Scientific
Cook Group
Hikma Pharmaceuticals
Nippon Kayaku
Novartis AG
Pfizer Inc.
Spectrum Pharmaceutical
Roche Holding AG
Celgene
Bayer AG
Merck & Co., Inc.
SingHealth
Segment by Type:
Chemotherapeutic Agents
Radio Therapeutic Agents
Drug-eluting Particles
Others
Segment by Application
Hospitals
Clinics
Cancer Research Centers
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Transarterial Chemoembolization (TACE) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Transarterial Chemoembolization (TACE) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Transarterial Chemoembolization (TACE) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Transarterial Chemoembolization (TACE) Product Introduction
1.2 Global Transarterial Chemoembolization (TACE) Market Size Forecast
1.3 Transarterial Chemoembolization (TACE) Market Trends & Drivers
1.3.1 Transarterial Chemoembolization (TACE) Industry Trends
1.3.2 Transarterial Chemoembolization (TACE) Market Drivers & Opportunity
1.3.3 Transarterial Chemoembolization (TACE) Market Challenges
1.3.4 Transarterial Chemoembolization (TACE) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Transarterial Chemoembolization (TACE) Players Revenue Ranking (2023)
2.2 Global Transarterial Chemoembolization (TACE) Revenue by Company (2019-2024)
2.3 Key Companies Transarterial Chemoembolization (TACE) Manufacturing Base Distribution and Headquarters
2.4 Key Companies Transarterial Chemoembolization (TACE) Product Offered
2.5 Key Companies Time to Begin Mass Production of Transarterial Chemoembolization (TACE)
2.6 Transarterial Chemoembolization (TACE) Market Competitive Analysis
2.6.1 Transarterial Chemoembolization (TACE) Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Transarterial Chemoembolization (TACE) Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transarterial Chemoembolization (TACE) as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Chemotherapeutic Agents
3.1.2 Radio Therapeutic Agents
3.1.3 Drug-eluting Particles
3.1.4 Others
3.2 Global Transarterial Chemoembolization (TACE) Sales Value by Type
3.2.1 Global Transarterial Chemoembolization (TACE) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Transarterial Chemoembolization (TACE) Sales Value, by Type (2019-2030)
3.2.3 Global Transarterial Chemoembolization (TACE) Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Cancer Research Centers
4.2 Global Transarterial Chemoembolization (TACE) Sales Value by Application
4.2.1 Global Transarterial Chemoembolization (TACE) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Transarterial Chemoembolization (TACE) Sales Value, by Application (2019-2030)
4.2.3 Global Transarterial Chemoembolization (TACE) Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Transarterial Chemoembolization (TACE) Sales Value by Region
5.1.1 Global Transarterial Chemoembolization (TACE) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Transarterial Chemoembolization (TACE) Sales Value by Region (2019-2024)
5.1.3 Global Transarterial Chemoembolization (TACE) Sales Value by Region (2025-2030)
5.1.4 Global Transarterial Chemoembolization (TACE) Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
5.2.2 North America Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
5.3.2 Europe Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
5.4.2 Asia Pacific Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
5.5.2 South America Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
5.6.2 Middle East & Africa Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Transarterial Chemoembolization (TACE) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Transarterial Chemoembolization (TACE) Sales Value
6.3 United States
6.3.1 United States Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
6.3.2 United States Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
6.4.2 Europe Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
6.5.2 China Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030
6.5.3 China Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
6.6.2 Japan Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
6.7.2 South Korea Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
6.8.2 Southeast Asia Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Transarterial Chemoembolization (TACE) Sales Value, 2019-2030
6.9.2 India Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030
6.9.3 India Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Questex
7.1.1 Questex Profile
7.1.2 Questex Main Business
7.1.3 Questex Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.1.4 Questex Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.1.5 Questex Recent Developments
7.2 Siemens Healthcare GmbH
7.2.1 Siemens Healthcare GmbH Profile
7.2.2 Siemens Healthcare GmbH Main Business
7.2.3 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.2.4 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.2.5 Siemens Healthcare GmbH Recent Developments
7.3 Bellicum Pharmaceuticals Inc.
7.3.1 Bellicum Pharmaceuticals Inc. Profile
7.3.2 Bellicum Pharmaceuticals Inc. Main Business
7.3.3 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.3.4 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.3.5 Boston Scientific Recent Developments
7.4 Boston Scientific
7.4.1 Boston Scientific Profile
7.4.2 Boston Scientific Main Business
7.4.3 Boston Scientific Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.4.4 Boston Scientific Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.4.5 Boston Scientific Recent Developments
7.5 Cook Group
7.5.1 Cook Group Profile
7.5.2 Cook Group Main Business
7.5.3 Cook Group Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.5.4 Cook Group Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.5.5 Cook Group Recent Developments
7.6 Hikma Pharmaceuticals
7.6.1 Hikma Pharmaceuticals Profile
7.6.2 Hikma Pharmaceuticals Main Business
7.6.3 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.6.4 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.6.5 Hikma Pharmaceuticals Recent Developments
7.7 Nippon Kayaku
7.7.1 Nippon Kayaku Profile
7.7.2 Nippon Kayaku Main Business
7.7.3 Nippon Kayaku Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.7.4 Nippon Kayaku Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.7.5 Nippon Kayaku Recent Developments
7.8 Novartis AG
7.8.1 Novartis AG Profile
7.8.2 Novartis AG Main Business
7.8.3 Novartis AG Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.8.4 Novartis AG Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.8.5 Novartis AG Recent Developments
7.9 Pfizer Inc.
7.9.1 Pfizer Inc. Profile
7.9.2 Pfizer Inc. Main Business
7.9.3 Pfizer Inc. Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.9.4 Pfizer Inc. Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.9.5 Pfizer Inc. Recent Developments
7.10 Spectrum Pharmaceutical
7.10.1 Spectrum Pharmaceutical Profile
7.10.2 Spectrum Pharmaceutical Main Business
7.10.3 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.10.4 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.10.5 Spectrum Pharmaceutical Recent Developments
7.11 Roche Holding AG
7.11.1 Roche Holding AG Profile
7.11.2 Roche Holding AG Main Business
7.11.3 Roche Holding AG Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.11.4 Roche Holding AG Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.11.5 Roche Holding AG Recent Developments
7.12 Celgene
7.12.1 Celgene Profile
7.12.2 Celgene Main Business
7.12.3 Celgene Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.12.4 Celgene Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.12.5 Celgene Recent Developments
7.13 Bayer AG
7.13.1 Bayer AG Profile
7.13.2 Bayer AG Main Business
7.13.3 Bayer AG Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.13.4 Bayer AG Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.13.5 Bayer AG Recent Developments
7.14 Merck & Co., Inc.
7.14.1 Merck & Co., Inc. Profile
7.14.2 Merck & Co., Inc. Main Business
7.14.3 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.14.4 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.14.5 Merck & Co., Inc. Recent Developments
7.15 SingHealth
7.15.1 SingHealth Profile
7.15.2 SingHealth Main Business
7.15.3 SingHealth Transarterial Chemoembolization (TACE) Products, Services and Solutions
7.15.4 SingHealth Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)
7.15.5 SingHealth Recent Developments
8 Industry Chain Analysis
8.1 Transarterial Chemoembolization (TACE) Industrial Chain
8.2 Transarterial Chemoembolization (TACE) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Transarterial Chemoembolization (TACE) Sales Model
8.5.2 Sales Channel
8.5.3 Transarterial Chemoembolization (TACE) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Questex
Siemens Healthcare GmbH
Bellicum Pharmaceuticals Inc.
Boston Scientific
Cook Group
Hikma Pharmaceuticals
Nippon Kayaku
Novartis AG
Pfizer Inc.
Spectrum Pharmaceutical
Roche Holding AG
Celgene
Bayer AG
Merck & Co., Inc.
SingHealth
听
听
*If Applicable.
